K.J. Harrison & Partners Inc Increases Position in Hologic, Inc. $HOLX

K.J. Harrison & Partners Inc lifted its stake in Hologic, Inc. (NASDAQ:HOLX) by 72.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 52,500 shares of the medical equipment provider’s stock after acquiring an additional 22,000 shares during the period. K.J. Harrison & Partners Inc’s holdings in Hologic were worth $3,565,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in HOLX. US Bancorp DE grew its stake in Hologic by 1.3% in the third quarter. US Bancorp DE now owns 21,667 shares of the medical equipment provider’s stock valued at $1,462,000 after purchasing an additional 282 shares during the last quarter. Fox Run Management L.L.C. boosted its holdings in shares of Hologic by 173.5% in the 3rd quarter. Fox Run Management L.L.C. now owns 10,321 shares of the medical equipment provider’s stock valued at $697,000 after buying an additional 6,547 shares in the last quarter. MAI Capital Management grew its position in shares of Hologic by 818.3% in the 3rd quarter. MAI Capital Management now owns 5,978 shares of the medical equipment provider’s stock worth $403,000 after buying an additional 5,327 shares during the last quarter. Mufg Securities Americas Inc. grew its position in shares of Hologic by 21.4% in the 3rd quarter. Mufg Securities Americas Inc. now owns 5,998 shares of the medical equipment provider’s stock worth $405,000 after buying an additional 1,059 shares during the last quarter. Finally, AXQ Capital LP bought a new position in shares of Hologic during the 3rd quarter worth approximately $239,000. Institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Weiss Ratings restated a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. BNP Paribas Exane cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price objective for the company. in a research report on Friday, November 21st. Argus lowered Hologic from a “buy” rating to a “hold” rating in a research report on Monday, January 12th. Evercore cut Hologic from an “outperform” rating to an “in-line” rating and decreased their price target for the company from $79.00 to $78.00 in a research note on Monday, January 5th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Hologic in a report on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $78.42.

Hologic Stock Performance

HOLX opened at $75.34 on Thursday. The company has a current ratio of 4.04, a quick ratio of 3.32 and a debt-to-equity ratio of 0.48. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $75.49. The firm has a 50 day moving average of $74.94 and a two-hundred day moving average of $72.04. The firm has a market capitalization of $16.82 billion, a PE ratio of 31.39, a P/E/G ratio of 2.25 and a beta of 0.72.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a net margin of 13.18% and a return on equity of 19.58%. The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period last year, the company earned $0.87 earnings per share. The firm’s revenue was up 2.5% on a year-over-year basis. On average, analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.